Pharmaceuticals News and Research

RSS

Social isolation the way to stop flu spreading

Australian researchers say isolation would slow down the spread of outbreaks of influenza.

3 May 2009

A negative mGluR5 allosteric modulator shows efficacy in treating acute migraine attacks

When migraine strikes, because of severe pain, often accompanied by nausea and sensitivity to light and sound, sufferers are effectively disabled for up to 72 hours.

30 Apr 2009

Oral delivery system for RNAi therapeutics

Researchers at the University of Massachusetts Medical School (UMMS) report on a novel approach to the delivery of small bits of genetic material in order to silence genes using "RNA interference"-and in the process, discovered a potent method of suppressing inflammation in mice similar to what occurs in a range of human diseases.

30 Apr 2009

Research may bring drugs with triple the absorbing power and lower toxic risks

Drug makers might be able to triple the absorbing power of some medications and lower toxic risks of others, as a result of a study at the University of Maryland, Baltimore on how bile acids travel through the gut.

29 Apr 2009

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by investigators from the Duke Clinical Research Institute (DCRI).

29 Apr 2009

Wyeth's Conbriza (bazedoxifene) approved in Europe for postmenopausal osteoporosis

Wyeth Pharmaceuticals has announced that the European Commission has granted marketing authorization for Conbriza (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.

27 Apr 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

Nanotechnology: Its Promise and Challenges - talk by Vicki Colvin

Vicki Colvin of Rice University will give a talk titled "Nanotechnology: Its Promise and Challenges" at the U.S. Department of Energy's Brookhaven National Laboratory on Thursday, May 14, at 4 p.m. in Berkner Hall. The talk is free and open to the public. Visitors to the Laboratory age 16 and older must carry a photo ID.

27 Apr 2009

New Federal Government rules on cancer treatment unfair

Critics say new measures proposed by the Australian Federal Government, due to come into force in July this year, will mean an end to Government subsidies for leftover cancer drugs - worth about $26 million a year - are unfair to both patients and pharmacists.

27 Apr 2009

New diagnostic technique found for most common bladder tumors

Making tumors inside the bladder fluoresce red under blue light allows physicians to more easily find and remove them, substantially reducing the rate at which these cancers come back, says a Mayo Clinic physician who is presenting results of a large, multicenter international clinical trial.

26 Apr 2009

IBM and Golden State Medical Supply create drug safety model to tackle counterfeiting

IBM and Golden State Medical Supply (GSMS) have announced the two companies have worked together to help drug companies comply with stringent prescription drug pedigree regulations in advance of state and federal mandates.

26 Apr 2009

Discrepancies between reports of HRT dangers and supporting data

In recent years, a series of highly publicized reports have warned of increases in breast cancer and other health problems in postmenopausal women who take hormone replacement therapy (HRT).

23 Apr 2009

Watson Pharmaceuticals files ANDAs for generic Mucinex

Watson Pharmaceuticals, Inc. has confirmed that it has filed two Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration seeking approval to market its guaifenesin extended-release 600mg and 1200mg tablets and its dextromethorphan HBr/guaifenesin extended-release 30mg/600mg and 60mg/1200mg tablets prior to the expiration of patents owned by Reckitt Benckiser Inc.

22 Apr 2009

Researchers create chemicals that kill the most deadly malaria-causing parasite

Researchers at the University of Leeds have developed chemicals which kill the most deadly malaria-causing parasite, Plasmodium falciparum - including those resistant to existing drugs.

22 Apr 2009

Lilly granted preliminary injunction to prevent launch of generic Raloxifene

Eli Lilly and Company has announced that the U.S. District Court for the Southern District of Indiana today issued a preliminary injunction to prevent the launch of a generic version of Lilly's medicine Evista (raloxifene HCl tablets) by Teva Pharmaceuticals until the Court renders its final ruling.

22 Apr 2009

AcelRx starts cancer breakthrough pain program

AcelRx Pharmaceuticals, Inc. has announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab product candidate for cancer breakthrough pain control.

22 Apr 2009

Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies

Peregrine Pharmaceuticals, Inc. has reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS) targeting antibodies.

22 Apr 2009

Pancreatic cancer cells targeted with combo therapy

A combination of two targeted therapies packs a powerful punch to kill pancreatic cancer cells in the laboratory, Mayo Clinic cancer researchers report.

21 Apr 2009

Ardea Biosciences announces positive results from a phase 1 study of lead candidate for hyperuricemia and gout

Ardea Biosciences, Inc. has announced positive results from a Phase 1 study in normal, healthy volunteers of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and a pilot Phase 2a proof-of-concept study in gout patients of RDEA594's prodrug, RDEA806 (RDEA806 is converted to RDEA594 in the body).

20 Apr 2009

Marine derived compound may lead to new leukemia treatments

Kapakahines, marine-derived natural products isolated from a South Pacific sponge in trace quantities, have shown anti-leukemia potential, but studies have been all but stalled by kapakahines' lack of availability.

20 Apr 2009